company background image
BGBIO logo

BerGenBio OB:BGBIO Stock Report

Last Price

NOK 10.37

Market Cap

NOK 313.2m

7D

68.9%

1Y

-31.8%

Updated

21 Nov, 2024

Data

Company Financials +

BerGenBio ASA

OB:BGBIO Stock Report

Market Cap: NOK 313.2m

BGBIO Stock Overview

A clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory diseases in Norway. More details

BGBIO fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Revenue is forecast to grow 86.17% per year

Earnings have grown 3.2% per year over the past 5 years

Risk Analysis

Highly volatile share price over the past 3 months compared to the Norwegian market

Has less than 1 year of cash runway

Earnings are forecast to decline by an average of 23.6% per year for the next 3 years

Makes less than USD$1m in revenue (NOK521K)

+ 3 more risks

BerGenBio ASA Competitors

Nordic Nanovector

OB:NANOV

NOK 231.8m

EXACT Therapeutics

OB:EXTX

NOK 186.1m

Thor Medical

OB:TRMED

NOK 554.3m

Lytix Biopharma

OB:LYTIX

NOK 296.7m

Price History & Performance

Summary of all time highs, changes and price drops for BerGenBio
Historical stock prices
Current Share PriceNOK 10.37
52 Week HighNOK 35.80
52 Week LowNOK 5.62
Beta1.64
11 Month Change17.97%
3 Month Change-5.75%
1 Year Change-31.79%
33 Year Change-99.45%
5 Year Change-99.36%
Change since IPO-99.59%

Recent News & Updates

Is BerGenBio (OB:BGBIO) In A Good Position To Deliver On Growth Plans?

Sep 21
Is BerGenBio (OB:BGBIO) In A Good Position To Deliver On Growth Plans?

Companies Like BerGenBio (OB:BGBIO) Could Be Quite Risky

Jun 02
Companies Like BerGenBio (OB:BGBIO) Could Be Quite Risky

Recent updates

Is BerGenBio (OB:BGBIO) In A Good Position To Deliver On Growth Plans?

Sep 21
Is BerGenBio (OB:BGBIO) In A Good Position To Deliver On Growth Plans?

Companies Like BerGenBio (OB:BGBIO) Could Be Quite Risky

Jun 02
Companies Like BerGenBio (OB:BGBIO) Could Be Quite Risky

Here's Why BerGenBio (OB:BGBIO) Must Use Its Cash Wisely

Dec 07
Here's Why BerGenBio (OB:BGBIO) Must Use Its Cash Wisely

BerGenBio (OB:BGBIO) Will Have To Spend Its Cash Wisely

Aug 24
BerGenBio (OB:BGBIO) Will Have To Spend Its Cash Wisely

BerGenBio (OB:BGBIO) Will Have To Spend Its Cash Wisely

Feb 06
BerGenBio (OB:BGBIO) Will Have To Spend Its Cash Wisely

Will BerGenBio (OB:BGBIO) Spend Its Cash Wisely?

Sep 26
Will BerGenBio (OB:BGBIO) Spend Its Cash Wisely?

Will BerGenBio (OB:BGBIO) Spend Its Cash Wisely?

Jun 11
Will BerGenBio (OB:BGBIO) Spend Its Cash Wisely?

Is BerGenBio (OB:BGBIO) In A Good Position To Deliver On Growth Plans?

Feb 17
Is BerGenBio (OB:BGBIO) In A Good Position To Deliver On Growth Plans?

We're Not Very Worried About BerGenBio's (OB:BGBIO) Cash Burn Rate

Sep 21
We're Not Very Worried About BerGenBio's (OB:BGBIO) Cash Burn Rate

It's Unlikely That The CEO Of BerGenBio ASA (OB:BGBIO) Will See A Huge Pay Rise This Year

Mar 13
It's Unlikely That The CEO Of BerGenBio ASA (OB:BGBIO) Will See A Huge Pay Rise This Year

We're Interested To See How BerGenBio (OB:BGBIO) Uses Its Cash Hoard To Grow

Feb 11
We're Interested To See How BerGenBio (OB:BGBIO) Uses Its Cash Hoard To Grow

What Kind Of Investors Own Most Of BerGenBio ASA (OB:BGBIO)?

Dec 21
What Kind Of Investors Own Most Of BerGenBio ASA (OB:BGBIO)?

Shareholder Returns

BGBIONO BiotechsNO Market
7D68.9%8.9%3.1%
1Y-31.8%-69.4%3.9%

Return vs Industry: BGBIO exceeded the Norwegian Biotechs industry which returned -69.4% over the past year.

Return vs Market: BGBIO underperformed the Norwegian Market which returned 3.9% over the past year.

Price Volatility

Is BGBIO's price volatile compared to industry and market?
BGBIO volatility
BGBIO Average Weekly Movement15.9%
Biotechs Industry Average Movement10.6%
Market Average Movement5.2%
10% most volatile stocks in NO Market10.6%
10% least volatile stocks in NO Market2.7%

Stable Share Price: BGBIO's share price has been volatile over the past 3 months compared to the Norwegian market.

Volatility Over Time: BGBIO's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Norwegian stocks.

About the Company

FoundedEmployeesCEOWebsite
200715Martin Olinwww.bergenbio.com

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory diseases in Norway. The company’s lead clinical asset is the Bemcentinib (BGB016), an inhibitor of AXL receptor tyrosine kinase (AXL), which is in phase 1b/2a clinical trial to treat non-small cell lung cancer; and (BGBC008), which is in phase 2 clinical trial to treat second-line non-small cell lung cancer (2L NSCLC). It develops Bemcentinib, which is in preclinical trial to treat acute respiratory distress syndrome; Tilvestamab (BGB149), anti-AXL monoclonal antibody, which in phase 1 clinical trial for the treatment of ovarian cancer; and Mipasetamab Uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors.

BerGenBio ASA Fundamentals Summary

How do BerGenBio's earnings and revenue compare to its market cap?
BGBIO fundamental statistics
Market capNOK 313.24m
Earnings (TTM)-NOK 152.29m
Revenue (TTM)NOK 521.00k

777.8x

P/S Ratio

-2.7x

P/E Ratio

Is BGBIO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BGBIO income statement (TTM)
RevenueNOK 521.00k
Cost of RevenueNOK 0
Gross ProfitNOK 521.00k
Other ExpensesNOK 152.81m
Earnings-NOK 152.29m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 19, 2025

Earnings per share (EPS)-3.90
Gross Margin100.00%
Net Profit Margin-29,230.13%
Debt/Equity Ratio0%

How did BGBIO perform over the long term?

See historical performance and comparison